Table 1.
Characteristics of enrolled patients.
| Total patients (N = 47) | Patients with paired NGS tests (N = 21) | |
|---|---|---|
| Age-median (range), years | 64 (38–86) | 44 (38–81) |
| Sex-no. (%) | ||
| Male | 19 (40.4) | 6 (28.6) |
| Female | 28(59.6) | 15 (71.4) |
| Smoking- no. (%) | ||
| Never | 30(63.8) | 14(66.7) |
| Former | 17(36.2) | 7(33.3) |
| Histology-no. (%) | ||
| Adenocarcinoma | 45(95.7) | 20(95.2) |
| NSCLC NOS | 2(4.3) | 1(4.8) |
| Primary EGFR mutation-No. (%) | ||
| Exon 19 deletion | 22(46.8) | 10(47.6) |
| L858R | 20(42.6) | 10(47.6) |
| L861R | 1(2.1) | 0 |
| G719A | 2(4.3) | 1(4.8) |
| 20 INS | 2(4.3) | 0 |
| L858R/T790M | 3(6.4) | 1(4.8) |
| PD-L1 expression- No. (%) | ||
| Negative | 8(17.0) | 3(14.3) |
| 1%–49% | 4(8.5) | 3(14.3) |
| ⩾50% | 4(8.5) | 3(14.3) |
| Unknown | 31(66.0) | 12(57.1) |
| Disease stage- No. (%) | ||
| IIIb/ IIIc | 4(8.5) | 2(9.5) |
| IV | 43(91.5) | 19(90.5) |
| Metastasis sites- No. (%) | ||
| Lung | 22(46.8) | 9(42.9) |
| Bone | 26(55.3) | 10(47.6) |
| Pleural | 17(36.2) | 10(47.6) |
| Brain | 19(40.4) | 9(42.9) |
| Liver | 8(17.0) | 6(28.6) |
The demographics, histology, metastasis sites, PD-L1 expression and sensitizing EGFR mutation for the two cohorts are shown.
Abbreviations: EGFR, epidermal growth factor receptor; NGS, next-generation sequencing; PD-L1, programmed death- ligand 1.